New Data Suggest Little Benefit Of Adding Heart Valve Repair To Bypass Surgery In Patients With Coronary Heart Disease
Results Presented at American Heart Association's Scientific Sessions 2014
NEW YORK, Nov. 18, 2014 /PRNewswire-USNewswire/ -- The addition of mitral valve (MV) repair (a valve of the heart) to coronary artery bypass grafting (CABG), a type of open-heart surgery, did not result in significant benefit to the patient and was associated with increased risk of neurological events. Therefore, the routine addition of MV repair to CABG in patients with moderate IMR did not demonstrate a clinically meaningful advantage.
The Cardiothoracic Surgical Trials Network (CTSN) is reporting results for the first time from a clinical trial of patients who have a complication of coronary heart disease known as moderate ischemic mitral regurgitation (IMR). Study findings were presented today at the American Heart Association's Scientific Sessions 2014.
"The results of this study suggest there is little benefit to what is often considered a routine addition to the open-heart procedure of CABG for patients with moderate IMR," said Robert Michler, M.D., professor and chairman, Department of Cardiothoracic and Vascular Surgery, and co-director of The Montefiore Einstein Center for Heart and Vascular Care, and senior study author. "Although the one-year data are very compelling, long-term follow-up is necessary to determine whether the lower prevalence of IMR seen at one year will translate into any clinical benefit for patients undergoing mitral valve repair."
IMR occurs when blood backflows into the left atrium from the left ventricle of the heart due to improper closure of the MV. The condition often develops as a complication of a heart attack and subsequent enlargement of the left ventricle, the heart's main pumping chamber. Functional IMR affects 1.6 million to 2.8 million patients in the U.S. and is associated with a doubling in mortality among patients with mild or greater degrees of mitral regurgitation after a heart attack. The optimal treatment of IMR remains controversial and unclear.
"We have not had clear evidence for treatment, so recommendations vary greatly from surgeon-to-surgeon, cardiologist-to-cardiologist and institution to institution with perhaps one-third opting for valve repair in addition to CABG," said Peter K. Smith, M.D., professor and division chief, Cardiovascular and Thoracic Surgery, Duke University School of Medicine, and the study's primary author. "This study provides some needed clarity, but it's also important to note we must keep following these patients beyond a year, because their outcomes may change over time."
The prospective, multi-center, controlled clinical trial randomly assigned 301 patients with moderate IMR to CABG alone or CABG with MV repair. The primary endpoint was left ventricular end systolic volume (LVESVI) at one-year, assessed using a Wilcoxon rank sum test categorizing deaths as the lowest LVESVI rank.
One-year mortality was 6.7 percent in CABG/MV repair patients versus 7.3 percent in CABG patients. There were no observed differences in MACCE, death, readmissions, functional status or quality-of-life at one-year.
"This comparative effectiveness trial provides insights that should be practice-changing," said Annetine Gelijns, Ph.D., professor and chair of the Department of Population Health Science and Policy at Icahn School of Medicine at Mount Sinai, who is the corresponding author for the NEJM study and principal investigator for the Data and Clinical Coordinating Center (DCC) at Mount Sinai for the NIH-sponsored CTSN.
"There was equivalent and impressive positive remodeling of the left ventricle in both the CABG and CABG-plus-MV repair groups," said John Puskas, M.D., professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai and chairman of the Department of Cardiovascular Surgery at Mount Sinai Beth Israel. Dr Puskas serves on the Steering Committee of the NIH Cardiothoracic Surgical Trials Network and is an author of the study. "This, and the excellent one-year survival, show that surgical performance by the sites was outstanding and adds weight to our findings."
The CTSN has eight core clinical centers in the U.S. and Canada, including, but not limited to, Montefiore Einstein Heart Center, Duke University and the Icahn School of Medicine at Mount Sinai.
This study was presented as the Late-Breaking Clinical Trial (Abstract 49403): The Surgical Treatment of Moderate Ischemic Mitral Regurgitation: A Randomized Clinical Trial From The Cardiothoracic Surgical Trials Network
About Montefiore Health System
Montefiore Health System is a premier academic health system and the University Hospital for Albert Einstein College of Medicine. Combining nationally-recognized clinical excellence with a population health perspective that focuses on the comprehensive needs of the communities it serves, Montefiore delivers coordinated, compassionate, science-driven care where, when and how patients need it most. Montefiore consists of six hospitals and an extended care facility with a total of 2,080 beds, a School of Nursing, and state-of-the-art primary and specialty care provided through a network of more than 150 locations across the region, including the largest school health program in the nation and a home health program. The Children's Hospital at Montefiore is consistently named in U.S. News' "America's Best Children's Hospitals." Montefiore's partnership with Einstein advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. The health system derives its inspiration for excellence from its patients and community, and continues to be on the frontlines of developing innovative approaches to care. For more information please visit www.montefiorehealthsystem.org. Follow us on Twitter; like us on Facebook; view us on YouTube.
About Duke University School of Medicine
Duke University School of Medicine is ranked 8th among medical schools nationwide by U.S. News & World Report. It is one of the largest biomedical research enterprises in the country, with more than $600 million in sponsored research expenditures annually.
The School of Medicine is part of Duke Medicine, which also includes Duke University School of Nursing with Duke University Health System. The Health System encompasses Duke University Hospital, Durham Regional Hospital, Duke Raleigh Hospital, Duke Primary Care, Private Diagnostic Clinic, Duke Home and Hospice, Duke Health and Wellness, and multiple affiliations. The flagship Duke University Hospital is consistently ranked among the nation's top hospitals, and is the No. 1 hospital in North Carolina and in the Triangle, according to U.S. News & World Report.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
For more information, visit http://www.mountsinai.org/
Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter: @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy
SOURCE Montefiore Health System
Share this article